

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/gs-22-701">https://dx.doi.org/10.21037/gs-22-701</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data in particular will be shared, and we also found the correlation between the coexistence of the BRAF <sup>V600E</sup> mutation and PD-L1 with RFS in early-stage PTC, which has seldom been provided in previous studies.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival data may be updated over time.
7	To whom will you share the data?	Medical oncologists and thyroid surgeons who are interested in studies of BRAF <sup>V600E</sup> mutation and PD-L1 in early-stage PTC.
8	For what type of analysis or purpose?	For analysis to evaluate the prognostic ability of BRAF <sup>V600E</sup> mutation and PD-L1 with recurrence in early PTC patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: milizhang5@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.